Psilocybin-assisted therapy shows promise for veterans with severe treatment-resistant PTSD in a small open-label pilot study with notable symptom reductions

Psilocybin-assisted therapy may reduce severe treatment-resistant PTSD symptoms in military veterans, based on an open-label pilot study that reported substantial symptom improvements after treatment. The work centers on veterans who had not responded adequately to existing options and evaluates whether psychedelic-assisted therapy could offer a new clinical pathway. The reported findings point to meaningful reductions in PTSD severity, with the intervention combining psilocybin administration and therapeutic support rather than drug exposure alone. The small sample size and lack of a control group limit strong causal conclusions, but the results support further investigation in larger randomized trials. PTSD in veterans remains difficult to treat when standard approaches fail, making early signals from novel interventions especially important. Psilocybin's therapeutic potential in this context matters because it could expand treatment options for a population with high symptom burden and limited alternatives.